30 closest matches · ranked by relevance
Minimal Change Disease
Primary: Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks — 21; 17 Participants — p=0.12
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
FSGS · MCD · Focal Segmental Glomerulosclerosis
Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg
Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
Glomerulonephritis, Membranous
Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7
Nephrotic Syndrome · Focal Segmental Glomerulosclerosis · Minimal Change Disease
Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Idiopathic Membranous Nephropathy
Primary: Remission Status — 39; 13 Participants — p=0.001
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Lupus Nephritis
Primary: Induction Phase: Number of Patients Showing Treatment Response — 98; 104; 87; 81 participants — p=0.478
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Lupus Nephritis
Primary: Number of Patients With Complete Remission — 8; 8; 34; 31 Participants
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Membranoproliferative Glomerulonephritis
Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Lupus Nephritis
Primary: Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 — 26.4; 30.6; 30.6; 15.3…
Fibrosis · Focal Glomerulosclerosis · Kidney Failure
Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01
Granulomatosis With Polyangiitis (Wegener's) (GPA) · Microscopic Polyangiitis (MPA)
Primary: Composite of i) All-cause Mortality or ii) End-stage Renal Disease — 100; 109 Participants
Fibrillary Glomerulonephritis
Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072
Anti-Glomerular Basement Membrane Antibody Disease
Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Kidney Transplant
Primary: Graft Survival — 13; 7 participants — p=0.849
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
IgA Nephropathy · Lupus Nephritis · Membranous Nephropathy
Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio
Glomerulonephritis, Membranous · antiPLA2R Positive
Primary: Number of Participants With Adverse Events — 15; 12 Participants
Autoimmune Disease
Primary: Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) — 2.28; 2.02; -0.28 Scores on a scale
IgA Nephropathy
Primary: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 — 0.85; 0.80; 0.76; 0.69 Ratio to baseline…